Mostrando postagens com marcador Novel drugs. Mostrar todas as postagens
Mostrando postagens com marcador Novel drugs. Mostrar todas as postagens

sexta-feira, 29 de maio de 2015

‘$5 Insanity’: What You Should Know About Flakka



                                         May 21, 2015 -- Some call it “$5 Insanity.”


Flakka, a new designer drug, is surging in popularity. Poison control centers in states including Florida, Alabama, Mississippi, and Texas are responding to an increasing number of incidents involving it.

Here’s what you need to know:

What is flakka?

It’s a man-made stimulant called an alphaPVP. It’s similar to “bath salts,” another dangerous drug that’s grabbed headlines in recent years.

Its off-white, coarse crystals sell for as little as $5 a hit. The name comes from la flaca, a Spanish club-slang term for a sexy, skinny girl.

“It looks like aquarium gravel,” says Alfred Aleguas, PharmD, managing director of the Florida Poison Information Center, Tampa.

How is it used?

People have tried taking it in a number of ways, says Jeffrey Bernstein, MD, medical director of the Florida Poison Information Center, Miami.

Those ways include:

    Snorting
    Mixing with food
    Drinking like a tea
    Pressing into pill form
    Inserting it into the rectum
    Vaping in an e-cigarette
    Injecting

“With injecting, you’re really asking for trouble, because the drug is likely to be cut with … dirt, with talc, who knows what else -- and you’re putting all that in your veins,” Bernstein says.

How does it work on the brain?

Users feel a sense of euphoria, Bernstein says. “It plays with your neurotransmitters, [brain chemicals] like dopamine and serotonin.”

That can lead to a state called excited or agitated delirium in a high that lasts for several hours.

What are the risks?

People who are high on flakka often lose touch with reality, Aleguas says.

“They don’t know what they’re doing, they’re hallucinating, they’re paranoid, they’re aggressive, they’re super-agitated,” he says. “That’s why you see news stories of people running down the street naked, banging on cars in traffic and just crazy, crazy stuff.”

Other health effects that Aleguas and Bernstein often see include:

Another dangerous effect is hyperthermia, or elevated body temperature, which Bernstein says can reach 108 degrees. At that temperature, he says, blood can no longer clot and a person starts to bleed internally.
..

“They bleed and they go into multi-organ failure,” he says. “Lung, liver, kidney, and brain injury can each occur when their temperature stays too high for too long.”

In an emergency room, doctors attempt to cool the person, to calm them. They may also use diazepam, midazolam, or another similar drug to slow a user’s heartbeat.

“We give them symptomatic and supportive care, try to keep them from hurting themselves and hospital staff,” he says.

Who's using flakka?

Bernstein says most users are male and in their teens, 20s, or 30s, although some are older.

“I haven’t seen any regular users,” he says. “It tends to be used sporadically and is associated with concerts and parties and things like that.”

And those users don’t always know what they’re getting, says Bernstein, who gets a call about flakka every day, and more on the weekends. About one-third of calls are from users looking for help, he says, while the others are from emergency personnel caring for users and looking for guidance.

“There’s no quality control on the street, so no one knows for sure what they’re taking,” he says. “Just because they bought something called flakka, no one knows if that’s really what they used, much less what kind of concentration you’re getting. It’s an unknown drug at an unknown dose, and any dose is abuse.”
“They bleed and they go into multi-organ failure,” he says. “Lung, liver, kidney, and brain injury can each occur when their temperature stays too high for too long.”


In an emergency room, doctors attempt to cool the person, to calm them. They may also use diazepam, midazolam, or another similar drug to slow a user’s heartbeat.

“We give them symptomatic and supportive care, try to keep them from hurting themselves and hospital staff,” he says.

Who's using flakka?

Bernstein says most users are male and in their teens, 20s, or 30s, although some are older.

“I haven’t seen any regular users,” he says. “It tends to be used sporadically and is associated with concerts and parties and things like that.”

And those users don’t always know what they’re getting, says Bernstein, who gets a call about flakka every day, and more on the weekends. About one-third of calls are from users looking for help, he says, while the others are from emergency personnel caring for users and looking for guidance.

“There’s no quality control on the street, so no one knows for sure what they’re taking,” he says. “Just because they bought something called flakka, no one knows if that’s really what they used, much less what kind of concentration you’re getting. It’s an unknown drug at an unknown dose, and any dose is abuse.”

                                       source to this post : www.webmd.com

quarta-feira, 1 de outubro de 2014

Novel Drugs Target Tough-to-Treat Bacteria

 

Published: Sep 9, 2014

Action Points

WASHINGTON - Researchers described early progress in the development of new agents that target difficult-to-treat Gram-negative resistant bacteria, including one drug already in early human testing that uses a "Trojan Horse" concept.

In preclinical testing in a mouse model, the parenteral siderophore cephalosporin named S-649266 showed in vitro and in vivo effectiveness in killing multidrug-resistant Pseudomonas and Acinetobacter species, and carbapenem-resistant Enterobacteriaceae in rodent models of thigh and lung infections, reported Yoshinori Yamano, PhD, vice president of medical research laboratories at Shionogi and Co., based in Osaka, Japan.

Also, in testing among healthy volunteers, 54 individuals were able to tolerate up to 2 g of S-649266, reported Yutaka Saisho, a researcher with Shionogi, at the Interscience Conference on Antimicrobial Agents and Chemotherapy. One of the volunteers had to withdraw from the study due to adverse thyroid tests, but there were no serious adverse events.

As a result of these positive results, the company had begun phase II studies of the drug, said Tsutae Den Nagata, MD PhD, chief medical officer for Shionogi.

Yamano described how the "Trojan Horse" effect allows S-694266 to get into the cell where it can kill the drug-resistant organism.

Gram-negative bacteria acquire iron which is necessary for growth and multiplication, and S-649266 binds to iron. When Gram-negative bacteria acquire iron bound to S-649266, they also absorb S-649266, transporting the drug through the outer membrane into the periplasmic space where it binds to penicillin-binding proteins and disrupts cell wall synthesis, he explained.

This use of the iron uptake system may allow S-649266 to be an effective approach to treat Gram-negative bacterial infections that are not able to be treated by available antibiotics, the researchers said.

"These studies target ... the most important problem in hospitals today, and that is the multidrug-resistant Gram-negative organisms," commented Richard Wenzel, MD, professor and chairman of internal medicine at the Virginia Commonwealth University Medical Center in Richmond.

"Clinicians are very comfortable using cephalosporins," he explained to MedPage Today. "With years of use of the carbapenems, the organisms - which are much smarter than we are -- have built up resistance, so we have very few drugs to treat carbapenem-resistant rods. Two years ago we had no drugs in the pipeline to treat these metallo-beta-lactamases and none for multidrug-resistant Pseudomonas, so if I sound excited it is because clinically we really haven't had anything, and here is a promising drug."

S-649266 was one of several drugs featured in an ICAAC symposium dedicated to new treatments in the development pipeline. Other drugs highlighted were:

  • AA139 targets the outer membrane of Gram-negatives such as Pseudomonas aeruginosa (Adenium Biotech).
  • ASP2397 has potent fungicidal activity against Aspergillus (Astellas Pharma).
  • TD-1607 is a glycoprotein-cephalosporin for multidrug-resistant Gram-positive infections (Theravance Biopharma).
  • OP0595 is a new series beta-lactamase inhibitor (Meiji Seika Pharma).

Primary source: Interscience Conference on Antimicrobial Agents and Chemotherapy
Source reference: Saisho Y, et al "S-694266, a novel siderophore cephalosporin for gram negative bacterial infections: Pharmacokinetics, safety and tolerability in healthy subjects" ICAAC 2014; Abstract F-1564.

Additional source: Interscience Conference on Antimicrobial Agents and Chemotherapy
Source reference:Yamano Y, et al "A parenteral siderophore cephalosporin S-649266 active against MDR Gram-negative pathogens" ICAAC 2014.